Loading…
Loading…
CMRA does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CMRA and 80,000+ other tickers.
See exactly how CMRA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CMRA and 80,000+ other tickers.
Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms. Currently, the company is progressing two main product candidates: CLS-001, an early-stage "biobetter" designed to treat inflammatory bowel conditions like Crohn's and Ulcerative Colitis, and CLS-002, another preclinical biobetter aimed at diverse oncology indications. Established in 2014, Comera Life Sciences is headquartered in Woburn, Massachusetts.
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Comera Life Sciences (NASDAQ: CMRA - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Valuation and Earnings This table compares
Comera Life Sciences (NASDAQ: CMRA - Get Free Report) and Palatin Technologies (PINK: PTNT - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation. Institutional and Insider Ownership 11.5% of
Zymeworks (NYSE: ZYME - Get Free Report) and Comera Life Sciences (NASDAQ: CMRA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Volatility and Risk Zymeworks has a beta
WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to maximize shareholder value.
WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value.